Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.

Crull MR, Ramos KJ, Caldwell E, Mayer-Hamblett N, Aitken ML, Goss CH.

BMC Pulm Med. 2016 Dec 7;16(1):176.

2.

Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data.

Wang W, Chen MH, Chiou SH, Lai HC, Wang X, Yan J, Zhang Z.

BMC Med Res Methodol. 2016 Sep 17;16(1):122. doi: 10.1186/s12874-016-0220-5.

3.

Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.

Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, Thompson V, Ramsey BW.

Clin Infect Dis. 2015 Sep 1;61(5):707-15. doi: 10.1093/cid/civ377. Epub 2015 May 13.

4.

Pseudomonas infection in antibody deficient patients.

Duraisingham SS, Hanson S, Buckland M, Grigoriadou S, Longhurst HJ.

Eur J Microbiol Immunol (Bp). 2014 Dec;4(4):198-203. doi: 10.1556/EUJMI-D-14-00026. Epub 2014 Dec 16.

5.

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.

Clin Infect Dis. 2015 Mar 1;60(5):703-12. doi: 10.1093/cid/ciu944. Epub 2014 Nov 25.

6.

Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.

Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ.

JRSM Short Rep. 2013 Jan;4(1):1. doi: 10.1258/shorts.2012.012018. Epub 2013 Jan 14.

7.

Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes.

Levy H, Wang X, Kaldunski M, Jia S, Kramer J, Pavletich SJ, Reske M, Gessel T, Yassai M, Quasney MW, Dahmer MK, Gorski J, Hessner MJ.

Genes Immun. 2012 Dec;13(8):593-604. doi: 10.1038/gene.2012.41. Epub 2012 Sep 13.

8.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.

Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR.

J Cyst Fibros. 2012 Jul;11(4):288-92. doi: 10.1016/j.jcf.2012.02.006. Epub 2012 Mar 20.

9.

Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.

Cardenas S, Scuri M, Samsell L, Ducatman B, Bejarano P, Auais A, Doud M, Mathee K, Piedimonte G.

Am J Physiol Lung Cell Mol Physiol. 2010 Sep;299(3):L334-44. doi: 10.1152/ajplung.00017.2010. Epub 2010 Jun 11.

10.

Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.

Yan J, Cheng Y, Fine JP, Lai HJ.

Biometrics. 2010 Jun;66(2):594-602. doi: 10.1111/j.1541-0420.2009.01288.x. Epub 2009 Jun 12.

11.

Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Lai HJ, Shoff SM, Farrell PM; Wisconsin Cystic Fibrosis Neonatal Screening Group.

Pediatrics. 2009 Feb;123(2):714-22. doi: 10.1542/peds.2007-3089.

Supplemental Content

Support Center